This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Looking into the phase 3 FRESCO-2 clinical trial data on fruquintinib in patients with refractory metastatic colorectal cancer.
Ticker(s): TAKWho's the expert?
Institution: Saddleback Medical Center
- Medical Director of Infusion Services at Saddleback Medical Center.
- Currently manages 20 patients with refractory metastatic colorectal cancer.
- Triple board certified in Internal Medicine, Hematology, and Oncology and treats adults with all types of solid tumors, malignant hematologic conditions, and benign disorders of the blood, including bleeding and clotting issues
Interview GoalTo discuss the standard of care and the potential of fruquintinib, a selective oral inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3 being developed by Takeda and Hutchmed for the treatment of pretreated metastatic colorectal cancer
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
